SINGAPORE - Media OutReach Newswire - 15 November 2024 - Woh Hup, an esteemed name in the world of Asian sauces, proudly ...
The Biden administration is facing backlash after it was revealed that a top official would be participating in a forum ...
The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...
Sporting News on MSN1d
Sea Eagles add two new recruits while prospect re-signsManly have confirmed the arrival of two new recruits, while the Sea Eagles have also secured Raymond Tuaimalo Vaega on a ...
Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.
Syros will stop the study and review the clinical data more thoroughly, CEO Conley Chee said in a statement. The firm said the trial's failure to meet its primary endpoint means it is in default under ...
The Rock reveals his female empowerment song for the upcoming Moana 2 film. The WWE legend is busy with not one but two ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...
Moreover, CUSEF Founder and Chairman Emeritus Tung Chee-hwa was the vice chairman of the 12th National Committee of the Chinese People’s Political Consultative Conference (CPPCC), another Chinese ...
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback